IRD Q4 2024 Earnings — Opus Genetics, Inc. Revenue & Financial Results | Market Cap Arena

IRDOpus Genetics, Inc.

$349M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+154.4% YoY

Gross Profit

-$3M-80.8% margin

Operating Income

-$38M-884.0% margin

Net Income

-$35M-816.7% margin

EPS (Diluted)

$-1.11

QoQ Revenue Growth

+11.2%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$795,000

Balance Sheet

Total Assets

$37M

Total Liabilities

$30M

Stockholders' Equity

$7M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+154.4%
Gross Profit	-$3M	-$3M	-15.6%
Operating Income	-$38M	-$5M	-600.5%
Net Income	-$35M	-$5M	-632.7%